Israël - hébreu - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - תמיסה להזרקה - corifollitropin alfa 100 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israël - hébreu - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - תמיסה להזרקה - corifollitropin alfa 150 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israël - hébreu - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - nafarelin acetate - תמיסה לאף - nafarelin acetate 2 mg/ml - nafarelin - nafarelin - - controlled ovarian stimulation programmes prior to in-vitro fertilisation.- hormonal management of endometriosis, including pain relief and reduction of endometrial lesions. - uterine fibroids.

Israël - hébreu - Ministry of Health

h.a. systems dental imports (2002), ltd - minocycline as hydrochloride - אבקה מסיסה - minocycline as hydrochloride 1 mg - minocycline - minocycline - arestin is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. arestin may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing.

Israël - hébreu - Ministry of Health

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

Israël - hébreu - Ministry of Health

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

Israël - hébreu - Ministry of Health

eli lilly israel ltd - olanzapine as pamoate monohydrate 405 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

Israël - hébreu - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 20 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

Israël - hébreu - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 30 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient.treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

Israël - hébreu - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.